DBV Technologies (DBVT) Stock Price, News & Analysis

Company Overview

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy solutions for food and environmental allergies. At the core of its research is the Viaskin® platform, an epicutaneous patch technology designed to deliver micro-doses of allergen through intact skin to elicit desensitization while minimizing systemic exposure. The company’s lead program, Viaskin Peanut, is being evaluated in pivotal Phase III trials in both the United States and Europe, offering a novel approach to addressing one of the most common and potentially severe food allergies in children and adults.

Beyond its peanut allergy program, DBV Technologies is advancing additional Viaskin immunotherapies targeting cow’s milk allergy, atopic dermatitis associated with food allergies, and other allergens such as hen’s egg and cat dander. These programs are at various stages of clinical development, highlighting the platform’s versatility and the company’s commitment to addressing unmet medical needs in allergy care. DBV collaborates with leading academic institutions and regulatory authorities to design and execute trials that meet rigorous safety and efficacy standards.

Founded in 2002 and headquartered in Bagneux, France, DBV Technologies also maintains a presence in Marlborough, Massachusetts, to support its North American operations. The company was co-founded by renowned allergists and scientists, and its leadership team is headed by CEO Marco Zannoni, whose experience spans global product development and regulatory strategy. DBV’s scientific advisory board comprises experts in allergy and immunology, reinforcing its strategic vision to transform the treatment landscape for allergic diseases worldwide.

Key Stats

• Today's Range: $10.55 to $11.99
• 50-Day Range: $7.74 to $11.54
• 52-Week Range: $2.20 to $12.78
• Volume: 29,062 shs
• Average Volume: 191,872 shs
• Market Capitalization: $316.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.75
• Consensus Rating: Moderate Buy

DBV Technologies Stock Analysis - MarketRank™

DBV Technologies scored higher than 75% of companies evaluated by MarketBeat, and ranked 244th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

DBV Technologies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for DBV Technologies are expected to grow in the coming year, from ($7.05) to ($5.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DBV Technologies is -2.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DBV Technologies is -2.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DBV Technologies has a P/B Ratio of 8.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of DBV Technologies has been sold short.

Short Interest Ratio / Days to Cover

DBV Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DBV Technologies has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DBV Technologies does not currently pay a dividend.

Dividend Growth

DBV Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.08% of the float of DBV Technologies has been sold short.

Short Interest Ratio / Days to Cover

DBV Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DBV Technologies has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.70

News Sentiment

DBV Technologies has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for DBV Technologies this week, compared to 2 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, DBV Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $730.00 in company stock.

Percentage Held by Insiders

Only 1.44% of the stock of DBV Technologies is held by insiders.

Percentage Held by Institutions

71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DBVT Stock Analysis - Frequently Asked Questions

How have DBVT shares performed this year?

DBV Technologies' stock was trading at $3.09 on January 1st, 2025. Since then, DBVT shares have increased by 273.4% and is now trading at $11.5390.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) issued its quarterly earnings results on Friday, April, 11th. The company reported ($1.10) EPS for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative net margin of 3,249.99% and a negative trailing twelve-month return on equity of 278.24%.

When did DBV Technologies' stock split?

DBV Technologies shares reverse split before market open on Friday, November 29th 2024.The 1-5 reverse split was announced on Monday, November 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of DBV Technologies?

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Meta Platforms (META), Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 4/11/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DBVT
• CIK: 1613780
• Web: www.dbv-technologies.com
• Phone: (315) 542-7878
• Fax: 33-1-43-26-10-83
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.75
• High Stock Price Target: $21.00
• Low Stock Price Target: $7.25
• Potential Upside/Downside: +27.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.92 million
• Net Margins: -3,249.99%
• Pretax Margin: -3,249.79%
• Return on Equity: -278.24%
• Return on Assets: -140.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.72
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.42 per share
• Price / Book: 8.13

Miscellaneous

• Outstanding Shares: 27,390,000
• Free Float: 26,996,000
• Market Cap: $316.05 million
• Optionable: Optionable
• Beta: -0.59